Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin

Drug Metabolism and Disposition

Volumn 40, Issue 4, 2012, Pages 772-778

  Sadeque, Abu J M ^a   Usmani, Khawja A ^a   Palamar, Safet ^a,b   Cerny, Matthew A ^a,c   Chen, Weichao G ^a,d  

^a ARENA PHARMACEUTICALS   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; DRUG METABOLITE; EUGENOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B7; LORCASERIN; LORCASERIN N CARBAMOYL GLUCURONIDE; MEFENAMIC ACID; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE TISSUE; KIDNEY PARENCHYMA; LIVER; LIVER MICROSOME METABOLISM; LUNG PARENCHYMA; PRIORITY JOURNAL;

BENZAZEPINES; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; KIDNEY; KINETICS; LIVER; MICROSOMES; MOLECULAR STRUCTURE; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84863372539     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043448     Document Type: Article

References (40)

1. Beaulieu M, Lévesque E, Hum DW, and Bélanger A (1996) Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem 271:22855-22862. (Pubitemid 26304735)
2. Bock KW (2002) UDP-glucuronosyltransferases, in Enzyme Systems That Metabolise Drugs and Other Xenobiotics (Costas I ed) pp 281-318, Wiley & Sons, Ltd., West Sussex, UK.
3. Carmella SG, Le Ka KA, Upadhyaya P, and Hecht SS (2002) Analysis of N- and O-glucuronides of 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Chem Res Toxicol 15:545-550. (Pubitemid 34326937)
4. 2C receptor agonist, in healthy male volunteers (Abstract). Drug Metab Rev 40:205.
5. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, and Greenblatt DJ (2002) Stereoselective conjugation of oxazepam by human UDP glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 30:1257-1265. (Pubitemid 35265834)
6. Ethell BT, Riedel J, Englert H, Jantz H, Oekonomopulos R, and Burchell B (2003) Glucuronidation of HMR1098 in human microsomes: evidence for the involvement of UGT1A1 in the formation of S-glucuronides. Drug Metab Dispos 31:1027-1034. (Pubitemid 36980592)
7. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM, and BLOSSOM Clinical Trial Group (2011) A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 96:3067-3077.
8. Gaganis P, Miners JO, and Knights KM (2007) Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem Pharmacol 73:1683-1691. (Pubitemid 46527548)
9. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, Chase GA, Richie J, and Lazarus P (2007) The UDP glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-93- pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 16:823-828. (Pubitemid 46650589)
10. Gunduz M, Argikar UA, Baeschlin D, Ferreira S, Hosagrahara V, and Harriman S (2010) Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies. Drug Metab Dispos 38:361-367.
11. Hanioka N, Naito T, and Narimatsu S (2008) Human UDP- glucuronosyltransferases isoforms involved in bisphenol A glucuronidation. Chemosphere 74:33-36.
12. Hum DW, Bélanger A, Lévesque E, Barbier O, Beaulieu M, Albert C, Vallée M, Guillemette C, Tchernof A, Turgeon D, et al. (1999) Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 69:413-423. (Pubitemid 29305564)
13. Innocenti F, Iyer L, Ramírez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692. (Pubitemid 32374570)
14. Kerdpin O, Elliot DJ, Mackenzie PI, and Miners JO (2006) Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9. Drug Metab Dispos 34:1950-1953. (Pubitemid 44837754)
15. Kirsch M, Korth HG, Sustmann R, and de Groot H (2000) Carbon dioxide but not bicarbonate inhibits N-nitrosation of secondary amines. Evidence for amine carbamates as protecting entities. Chem Res Toxicol 13:451-461. (Pubitemid 30416340)
16. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glucuronosyltransferase gene family: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269. (Pubitemid 27358064)
17. Mano Y, Usui T, and Kamimura H (2007a) Inhibitory potential of nonsteroidal ant-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol 63:211-216. (Pubitemid 46147064)
18. Mano Y, Usui T, and Kamimura H (2007b) The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040-2044. (Pubitemid 350005193)
19. Meech R and Mackenzie PI (2010) UGT3A: novel UDP-glycosyltransferases of the UGT superfamily. Drug Metab Rev 42:45-54.
20. Miners JO and Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51:347-369.
21. Morgan M, Chen WC, Anderson CM, Prosser W, Donahue D, and Shanahan WR (2008) Pharmacokinetic properties, metabolism, and tolerability of lorcaserin in healthy volunteers. Annual Meeting of the Obesity Society; 2008 Oct 3-7; Phoenix, AZ. The Obesity Society, Silver Spring, MD.
22. Obach RS, Cox LM, and Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33:262-270. (Pubitemid 40216594)
23. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, and Coe JW (2006) Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121-130. (Pubitemid 43042653)
24. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
25. Ren Q, Murphy SE, Zheng Z, and Lazarus P (2000) O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDGP-glucuronosyltransferase 2B7 and 1A9. Drug Metab Dispos 28:1352-1360.
26. Schaefer WH (1992) Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver microsomes. Drug Metab Dispos 20:130-133.
27. Schaefer WH (2006) Reaction of primary and secondary amines to form carbamic acid glucuronides. Curr Drug Metab 7:873-881.
28. A receptor partial agonist in Sprague-Dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolites. Drug Metab Dispos 33:1688-1699.
29. Shaffer CL, Ryder TF, Venkatakrishnan K, Henne IK, and O'Connell TN (2009) Biotransformation of an α4β2 nicotinic acetylcholine receptor partial agonist in Sprague-Dawley rats and the dispositional characterization of its N-carbamoyl glucuronide metabolite. Drug Metab Dispos 37:1480-1489.
30. Segel HI (1976) Biochemical Calculations, 2nd ed, Wiley & Sons Ltd., New York.
31. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, and The Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363:245-256.
32. Straub K, Davis M, and Hwang B (1988) Benzazepine metabolism revisited. Evidence for the formation of novel amine conjugates. Drug Metab Dispos 16:359-366.
33. Tremaine LM, Stroh JG, and Ronfeld RA (1989) Characterization of a carbamic acid ester glucuronide of the secondary amine sertraline. Drug Metab Dispos 17:58-63. (Pubitemid 19058165)
34. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616. (Pubitemid 30340694)
35. Tukey RH and Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414. (Pubitemid 32179916)
36. Turgeon D, Carrier JS, Chouinard S, and Bélanger A (2003) Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos 31:670-676. (Pubitemid 36444177)
37. Turgeon D, Carrier JS, Lévesque E, Hum DW, and Bélanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787. (Pubitemid 32222427)
38. Ullrich D, Münzel PA, Beck-Gschaidmeier S, Schröder M, and Bock KW (1997) Drug-metabolizing enzymes in pharyngeal mucosa and in oropharyngeal cancer tissues. Biochem Pharmacol 54:1159-1162. (Pubitemid 27479030)
39. Usmani KA, Chen WG, and Sadeque AJ (2012) Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos 40:761-771.
40. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)